CNTA has 36-month beta value of 1.49. Analysts have mixed views on the stock, with 8 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CNTA is 84.83M, and currently, short sellers hold a 6.28% ratio of that float. The average trading volume of CNTA on May 23, 2025 was 923.52K shares.
CNTA) stock’s latest price update
Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA)’s stock price has decreased by -1.56 compared to its previous closing price of 12.82. However, the company has seen a 0.24% increase in its stock price over the last five trading sessions. globenewswire.com reported 2025-05-19 that BOSTON and LONDON, May 19, 2025 (GLOBE NEWSWIRE) — Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following investor conferences:
CNTA’s Market Performance
CNTA’s stock has risen by 0.24% in the past week, with a monthly drop of -3.15% and a quarterly drop of -24.11%. The volatility ratio for the week is 4.81% while the volatility levels for the last 30 days are 4.04% for Centessa Pharmaceuticals plc ADR The simple moving average for the last 20 days is -2.30% for CNTA stock, with a simple moving average of -17.19% for the last 200 days.
Analysts’ Opinion of CNTA
Many brokerage firms have already submitted their reports for CNTA stocks, with Chardan Capital Markets repeating the rating for CNTA by listing it as a “Buy.” The predicted price for CNTA in the upcoming period, according to Chardan Capital Markets is $30 based on the research report published on May 08, 2025 of the current year 2025.
Piper Sandler, on the other hand, stated in their research note that they expect to see CNTA reach a price target of $38. The rating they have provided for CNTA stocks is “Overweight” according to the report published on March 31st, 2025.
CNTA Trading at -6.25% from the 50-Day Moving Average
After a stumble in the market that brought CNTA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -33.89% of loss for the given period.
Volatility was left at 4.04%, however, over the last 30 days, the volatility rate increased by 4.81%, as shares sank -7.27% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -26.03% lower at present.
During the last 5 trading sessions, CNTA rose by +0.24%, which changed the moving average for the period of 200-days by +22.76% in comparison to the 20-day moving average, which settled at $12.92. In addition, Centessa Pharmaceuticals plc ADR saw -24.66% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CNTA starting from SAHA SAURABH, who sale 55,000 shares at the price of $12.71 back on May 20 ’25. After this action, SAHA SAURABH now owns 221,017 shares of Centessa Pharmaceuticals plc ADR, valued at $699,110 using the latest closing price.
SAHA SAURABH, the Officer of Centessa Pharmaceuticals plc ADR, proposed sale 55,000 shares at $12.74 during a trade that took place back on May 20 ’25, which means that SAHA SAURABH is holding shares at $700,700 based on the most recent closing price.
Stock Fundamentals for CNTA
The total capital return value is set at -0.39. Equity return is now at value -74.29, with -52.20 for asset returns.
Based on Centessa Pharmaceuticals plc ADR (CNTA), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -19.96. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is -41.79.
Currently, EBITDA for the company is -221.97 million with net debt to EBITDA at 0.45. The liquidity ratio also appears to be rather interesting for investors as it stands at 14.37.
Conclusion
To put it simply, Centessa Pharmaceuticals plc ADR (CNTA) has had a mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
